BioNTech and CureVac after takeover

BioNTech among top players in mRNA and vaccines after CureVac acquisition

The planned acquisition of CureVac announced yesterday makes strategic sense for BioNTech. BioNTech justifies the acquisition with its improved positioning in mRNA technologies. EconSight can confirm this from a patent perspective. In terms of world-class patents in mRNA technologies, BioNTech ranks third after the CureVac acquisition with 141 world-class patents, behind Moderna (252 world-class patents) and 10x Genomics (166 world-class patents).

Without a world-class focus, i.e. based on all mRNA patents, BioNTech is now in fourth place with 266 patents behind Roche (384), Alnylam (315) and Moderna (293).

The takeover also has a positive effect on the position in vaccines technologies, the traditional field of activity for BioNTech and CureVac. Here, the new company would rank second after the merger with 120 world-class patents, behind GSK with 159 world-class patents and ahead of Novartis with 116 world-class patents.

Overall, BioNTech/CureVac would rank fifth in vaccines with 249 patents, behind GSK (509), Merck and Co (383), Johnson and Johnson (281) and Boehringer (250).